<DOC>
	<DOCNO>NCT00000654</DOCNO>
	<brief_summary>To determine tolerance HIV-infected patient TID oral dos FIAU syrup 4 different dose level . To determine peak trough blood level FIAU metabolites two week oral dose FIAU . The pyrimidine nucleoside analog FIAC primary deaminate uracil metabolite FIAU highly specifically active compound vitro several herpes group virus , particularly herpes simplex virus ( HSV ) type 1 2 , varicella zoster ( VZV ) , cytomegalovirus ( CMV ) , well hepatitis B virus ( HBV ) . Since FIAU primary metabolite FIAC administration FIAU simplify metabolism FIAC , anticipate clinical study FIAC FIAU tolerate least well FIAC . A single-dose , pharmacokinetic ( blood level ) study show FIAC , take orally , readily absorb bloodstream , convert FIAU . Daily oral dos expect provide concentration FIAU exceed vitro minimum inhibitory concentration nearly herpes group virus .</brief_summary>
	<brief_title>The Tolerance HIV-Infected Patients With Herpes Group Virus Infections Oral Doses FIAU</brief_title>
	<detailed_description>The pyrimidine nucleoside analog FIAC primary deaminate uracil metabolite FIAU highly specifically active compound vitro several herpes group virus , particularly herpes simplex virus ( HSV ) type 1 2 , varicella zoster ( VZV ) , cytomegalovirus ( CMV ) , well hepatitis B virus ( HBV ) . Since FIAU primary metabolite FIAC administration FIAU simplify metabolism FIAC , anticipate clinical study FIAC FIAU tolerate least well FIAC . A single-dose , pharmacokinetic ( blood level ) study show FIAC , take orally , readily absorb bloodstream , convert FIAU . Daily oral dos expect provide concentration FIAU exceed vitro minimum inhibitory concentration nearly herpes group virus . HIV-infected patient Karnofsky score least 80 ( without document recurrent herpes group infection ) successively enter consecutively study , escalate dose cohort . There total 4 dose cohort FIAU patient take require amount FIAU syrup every 8 hour , 1 hour prior 3 hour meal , total 14 day . Entry new patient next high dose base result tolerance safety data prior cohort 10 receive 14 day therapy least 7 meet tolerance criterion . Although formally randomize due sequential nature study serious medical condition patient , every attempt avoid bias assign patient dose make . Patients enter start first dose cohort . Upon meet enrollment tolerance criterion dose escalation , 5 patient history chronic HBV infection surface antigen positive screen visit add end dose cohort . Plasma sample take determine peak trough level FIAU Days 1 , 3 , 7 , 14 last visit . Patients ongoing active infection follow culture ( HSV , VZV CMV ) test ( HBV ) Days 1 , 3 , 7 , 14 . Antiemetic therapy Reglan , Compazine , Trilafon give concomitantly discretion investigator tolerance determine antiemetic therapy ongoing . Patients advise avoid heavy exercise within 24 hour laboratory test .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Fialuridine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Pentamidine aerosol prophylaxis recurrent Pneumocystis carinii pneumonia ( PCP ) patient currently receive treatment . Zidovudine ( AZT ) . Prior Medication : Allowed : Zidovudine ( AZT ) patient take drug &gt; 6 week dose = &lt; 600 mg/day , &lt; 10 percent decrease hematocrit , neutrophil , platelet last 30 day . Patients must : Have diagnosis HIV infection ELISA Western blot . Be able participate outpatient . Be ambulatory . Have Grade 0 1 AIDS Clinical Trial Group toxicity grade specify laboratory test . Be competent sign inform consent . Be able cooperate treatment plan evaluation schedule . NOTE : The screening test must initiate complete within 4 week prior first dose FIAU , except diagnostic herpes simplex virus ( HSV ) , varicella zoster ( VZV ) , cytomegalovirus ( CMV ) culture may do previously . Concomitant disease allow : Stable mucocutaneous disease . Superficial uncomplicated infection thrush . Exclusion Criteria Coexisting Condition : Patients follow exclude : HIV waste syndrome ( involuntary weight loss &gt; 10 percent baseline body weight and/or chronic diarrhea weakness document fever least 30 day ) . Clinical xray evidence bronchitis , pneumonitis , pulmonary edema , effusion , suspect active tuberculosis . Any unstable medical condition include serious infection cardiovascular , oncologic , renal , hepatic condition . Primary initial infection herpes simplex ( HSV ) , varicella zoster ( VZV ) , hepatitis B ( HBV ) . Cytomegalovirus ( CMV ) end organ disease . Kaposi 's sarcoma require chemotherapy . Systemic fungal infection require amphotericin therapy . Diagnosis idiopathic thrombocytopenic purpura ( persistent platelet count &lt; 100000 platelets/mm3 = &gt; 3 month ) . Patients follow exclude : HIV waste syndrome . Clinical xray evidence bronchitis , pneumonitis , pulmonary edema , effusion , suspect active tuberculosis . Any unstable medical condition include serious cardiovascular , infection , oncologic , renal , hepatic condition . Primary initial infection herpes simplex ( HSV ) , varicella zoster ( VZV ) , hepatitis B ( HBV ) . Cytomegalovirus ( CMV ) end organ disease . Prior Medication : Excluded within 4 week study entry : Ganciclovir ( DHPG ) . Foscarnet . Interferon . Other drug putative antiviral activity ( except zidovudine ( AZT ) ) . Any immunostimulating drug specifically allow . Excluded within 1 week study entry : Acyclovir .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pyrimidine Nucleosides</keyword>
	<keyword>Herpesviridae Infections</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>